| Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial PF Dequin, N Heming, F Meziani, G Plantefève, G Voiriot, J Badié, ... Jama 324 (13), 1298-1306, 2020 | 495 | 2020 |
| Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma A Carpentier, F Laigle-Donadey, S Zohar, L Capelle, A Behin, A Tibi, ... Neuro-oncology 8 (1), 60-66, 2006 | 251 | 2006 |
| Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial RM Pressler, GB Boylan, N Marlow, M Blennow, C Chiron, JH Cross, ... The Lancet Neurology 14 (5), 469-477, 2015 | 241 | 2015 |
| Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis MC Vonk, Z Marjanovic, FHJ van den Hoogen, S Zohar, ... Annals of the rheumatic diseases 67 (1), 98-104, 2008 | 225 | 2008 |
| Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study A Carpentier, P Metellus, R Ursu, S Zohar, F Lafitte, M Barrie, Y Meng, ... Neuro-oncology 12 (4), 401-408, 2010 | 215 | 2010 |
| Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I–II study D Farge, JP Marolleau, S Zohar, Z Marjanovic, J Cabane, N Mounier, ... British journal of haematology 119 (3), 726-739, 2002 | 149 | 2002 |
| Dose‐finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method L Desfrere, S Zohar, P Morville, A Brunhes, S Chevret, G Pons, G Moriette, ... Journal of clinical pharmacy and therapeutics 30 (2), 121-132, 2005 | 146 | 2005 |
| The continual reassessment method: comparison of Bayesian stopping rules for dose‐ranging studies S Zohar, S Chevret Statistics in medicine 20 (19), 2827-2843, 2001 | 122 | 2001 |
| Late morbidity after colon interposition for corrosive esophageal injury: risk factors, management, and outcome. A 20-years experience M Chirica, N Veyrie, N Munoz-Bongrand, S Zohar, B Halimi, M Celerier, ... Annals of surgery 252 (2), 271-280, 2010 | 119 | 2010 |
| Risk factors for conversion and complications after unilateral laparoscopic adrenalectomy S Gaujoux, S Bonnet, M Leconte, S Zohar, J Bertherat, X Bertagna, ... Journal of British Surgery 98 (10), 1392-1399, 2011 | 103 | 2011 |
| Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial R Rouzier, S Gouy, F Selle, E Lambaudie, A Floquet, V Fourchotte, ... European journal of cancer 70, 133-142, 2017 | 102 | 2017 |
| Surgery for caustic injuries of the upper gastrointestinal tract M Chirica, M Resche-Rigon, NM Bongrand, S Zohar, B Halimi, JM Gornet, ... Annals of surgery 256 (6), 994-1001, 2012 | 94 | 2012 |
| Experimental designs for phase I and phase I/II dose-finding studies J O'Quigley, S Zohar British journal of cancer 94 (5), 609-613, 2006 | 92 | 2006 |
| CAPE COVID Trial Group and the CRICS-TriGGERSep Network. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a … PF Dequin, N Heming, F Meziani, G Plantefève, G Voiriot, J Badié, ... JAMA 324 (13), 1298-1306, 2020 | 73 | 2020 |
| Recommendations for the design of therapeutic trials for neonatal seizures JS Soul, R Pressler, M Allen, G Boylan, H Rabe, R Portman, P Hardy, ... Pediatric research 85 (7), 943-954, 2019 | 69 | 2019 |
| Efficient adaptive designs for clinical trials of interventions for COVID-19 N Stallard, L Hampson, N Benda, W Brannath, T Burnett, T Friede, ... Statistics in Biopharmaceutical Research 12 (4), 483-497, 2020 | 66 | 2020 |
| A Bayesian dose‐finding design for drug combination clinical trials based on the logistic model MK Riviere, Y Yuan, F Dubois, S Zohar Pharmaceutical statistics 13 (4), 247-257, 2014 | 66 | 2014 |
| A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia V Levy, S Zohar, C Bardin, A Vekhoff, D Chaoui, B Rio, O Legrand, ... British journal of cancer 95 (3), 253-259, 2006 | 66 | 2006 |
| Designs of drug-combination phase I trials in oncology: a systematic review of the literature MK Riviere, C Le Tourneau, X Paoletti, F Dubois, S Zohar Annals of Oncology 26 (4), 669-674, 2015 | 61 | 2015 |
| Dose‐finding designs using a novel quasi‐continuous endpoint for multiple toxicities M Ezzalfani, S Zohar, R Qin, SJ Mandrekar, MCL Deley Statistics in medicine 32 (16), 2728-2746, 2013 | 57 | 2013 |
